Top Markets
Coin of the day
Eli Lilly Eli Lilly

Eli Lilly

LLY
Clasificación en acciones #15
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals... Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Precio por acción
$910.55
Capitalización bursátil
$860.30B
Cambio (1 día)
0.44%
Cambio (1 año)
5.28%
País
US
Comercio Eli Lilly (LLY)

Categoría

Número de acciones en circulación de Eli Lilly (LLY)
Número de acciones en circulación al December 2025: 898.00M
Según los últimos informes financieros y el precio de las acciones de Eli Lilly, el número actual de acciones en circulación es 898.00M. Al final de December 2024, la empresa tenía 900.61M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Eli Lilly (LLY) desde 2000 hasta 2026
Acciones en circulación al final de cada año
Año Acciones en circulación Cambiar
2026 (TTM) 898.00M 0.00%
2025 898.00M -0.29%
2024 900.61M 0.14%
2023 899.38M -5.35%
2022 950.18M -0.36%
2021 953.65M -0.31%
2020 956.59M -0.10%
2019 957.53M -6.83%
2018 1.03B -2.31%
2017 1.05B -4.44%
2016 1.10B -0.40%
2015 1.11B -0.48%
2014 1.11B -0.55%
2013 1.12B -2.59%
2012 1.15B 2.92%
2011 1.11B 0.74%
2010 1.11B 0.68%
2009 1.10B 0.35%
2008 1.09B 0.37%
2007 1.09B 0.33%
2006 1.09B -0.08%
2005 1.09B 0.35%
2004 1.08B 0.74%
2003 1.08B -0.27%
2002 1.08B 0.12%
2001 1.08B -0.28%
2000 1.08B 0.00%
Acciones en circulación de empresas similares o competidores
Empresa Acciones en circulación Diferencia País
3.10B 245.21%
GB
2.43B 170.44%
US
1.78B 98.26%
US
1.91B 113.03%
CH
2.49B 177.27%
US